Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411120 | 1.00 | TSHR (0.46) | TSHRKIF11KMT2AATMLMNA | |
| SCHEMBL14848474 | 0.84 | SLC22A12 (0.40) | TSHRKIF11KMT2AALDH1A1KDM4E | |
| SCHEMBL1622124 | 0.82 | KIF11 (0.58) | TSHRKIF11KMT2ALMNATYR | |
| SCHEMBL14349289 | 0.81 | KMT2A (0.42) | TSHRKIF11KMT2AATMADRA2A | |
| SCHEMBL13147546 | 0.81 | KMT2A (0.38) | TSHRKIF11KMT2AATMADRA2A | |
| SCHEMBL14236551 | 0.81 | ADRA2A (0.39) | TSHRKMT2AATMADRA2AADRA2B | |
| SCHEMBL26800879 | 0.81 | KMT2A (0.38) | TSHRKIF11KMT2AATMADRA2A | |
| SCHEMBL10193119 | 0.81 | KMT2A (0.38) | TSHRKMT2AATMADRA2AADRA2B | |
| SCHEMBL10238573 | 0.81 | KMT2A (0.46) | KMT2AATMADRA2AADRA2BADRA2C | |
| SCHEMBL13657731 | 0.80 | RAB9A (0.56) | LMNAALDH1A1KDM4EPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 851 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328126-B2 | Norbornenylhydrocarbylene dihydrocarbylboranes and methods of making the same | PROMERUS, LLC (US) | 2016-05-03 | — | — | US | claimed |
| US-20150353582-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | PROMERUS, LLC (US) | 2015-12-10 | — | — | US | claimed |
| WO-2014121008-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | PROMERUS, LLC (US) | 2014-08-07 | — | — | WO | claimed |
| US-8106200-B2 | Pyridine borane complexes | BASF SE (DE) | 2012-01-31 | — | — | US | claimed |
| US-20110207934-A1 | PYRIDINE BORANE COMPLEXES | BASF SE (DE) | 2011-08-25 | — | — | US | claimed |
| EP-2066631-B1 | PYRIDINE BORANE COMPLEXES | BASF SE (DE) | 2011-04-06 | — | — | EP | claimed |
| EP-2066631-A1 | PYRIDINE BORANE COMPLEXES | BASF SE (DE) | 2009-06-10 | — | — | EP | claimed |
| WO-2008034886-A1 | PYRIDINE BORANE COMPLEXES | BASF SE (DE) | 2008-03-27 | — | — | WO | claimed |
| US-12503465-B2 | Process for preparing [3-chloro-2-[3-[2-[1-(2-chloroacetyl)-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]phenyl] methanesulfonate | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4077321-B1 | PROCESS FOR PREPARING [3-CHLORO-2-[3-[2-[1-(2-CHLOROACETYL)-4-PIPERIDYL]THIAZOL-4-YL]-4,5-DIHYDROISOXAZOL-5-YL]PHENYL] METHANESULFONATE | BAYER AG (DE) | 2025-06-25 | — | — | EP | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-7226950-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7214668-B2 | Phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503465-B2 | Process for preparing [3-chloro-2-[3-[2-[1-(2-chloroacetyl)-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]phenyl] methanesulfonate | CTPS2, DCPS, DHPS | TSHR 3200/4885KIF11 152/4885KMT2A 1646/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | TSHR 1824/4885KIF11 4336/4885KMT2A 3284/4885 |
| US-20150353582-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | CYP8B1, BDKRB1, CYP1B1 | TSHR 2733/4885KIF11 1681/4885KMT2A 2288/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | TSHR 3994/4885KIF11 1631/4885KMT2A 3434/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | TSHR 1793/4885KIF11 2928/4885KMT2A 1444/4885 |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | TSHR 166/4885KIF11 3546/4885KMT2A 1954/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | TSHR 3550/4885KIF11 3394/4885KMT2A 2885/4885 |
| US-20110207934-A1 | PYRIDINE BORANE COMPLEXES | NBAS, BRD8, PAXBP1 | TSHR 3483/4885KIF11 3996/4885KMT2A 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.